Gosset research
Reports: Report
Gosset reports matching these filters, newest first.
5 items Clear filters
Report
HCXT-2001: oral IL-23R inhibition
Inside the oral IL-23R program behind Gilead’s announced acquisition agreement: mechanism, clinical evidence and competition.
- External sample
Report · External · Slide deck
Asset due diligence: Frexalimab for relapsing multiple sclerosis (opens Slide deck on Google Drive)
Full due-diligence assessment of a drug asset: thesis, evidence, competitive landscape, IP, pricing, and risks.
- External sample
Report · External · Slide deck
Disease brief: IgA nephropathy (opens Slide deck on Google Drive)
A business development brief for a disease: unmet need, epidemiology, pipeline & competition, deals, and risk.
- External sample
Report · External · Google Sheets
Head-to-head results: IL-13 vs IL-4Rα biologics in atopic dermatitis (EASI-75, IGA 0/1) (opens Google Sheets on Google Drive)
Side-by-side comparison of trial outcomes for a drug class or indication. Covers safety, efficacy, patient population, and trial design.
- External sample
Report · External · Written report
Standard of care: Generalized myasthenia gravis (opens Written report on Google Drive)
The current standard of care for a given disease, grounded in drug labels and treatment guidelines.